Epidemiology, traditional and novel risk factors in coronary artery disease

Cardiology Clinics

Volumn 32, Issue 3, 2014, Pages 323-332

  Mack, Molly ^a   Gopal, Ambarish ^b  

^a Cardiopulmonary Research Science and Technology Institute   (United States)

^b THE HEART HOSPITAL BAYLOR PLANO   (United States)

Author keywords

Coronary artery disease; Epidemiology; Risk factors

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 6; MYELOPEROXIDASE;

ALCOHOL CONSUMPTION; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; EXERCISE; FAMILY HISTORY; FOOD INTAKE; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; OXYGEN CONSUMPTION; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SILENT MYOCARDIAL INFARCTION; SILENT MYOCARDIAL ISCHEMIA; SUDDEN CARDIAC DEATH; TOBACCO USE; HEALTH; MORBIDITY; PROCEDURES; RISK ASSESSMENT; SURVIVAL RATE; TRENDS;

CORONARY ARTERY DISEASE; GLOBAL HEALTH; HUMANS; MORBIDITY; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84905220424     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2014.04.003     Document Type: Review

References (122)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Go A.S., Mozaffarian D., Roger V.L., et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:399-410.
3. Lloyd-Jones D.M., Larson M.G., Beiser A., et al. Lifetime risk of developing coronary heart disease. Lancet 1999, 353:89.
4. Murphy S.L., Xu J., Kochanek K.D. Deaths: final data for 2010. Natl Vital Stat Rep 2013, 61(4).
5. Towfighi A., Zheng L., Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009, 169:1762-1766.
6. Deedwania P.C., Carbajal E.V. Silent myocardial ischemia. A clinical perspective. Arch Intern Med 1991, 151:2373.
7. Gordon T., Kannel W.B., Hjortland M.C., et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978, 89:157.
8. Lerner D.J., Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986, 111:383.
9. Kannel W.B. Prevalence and clinical aspects of unrecognized myocardial infarction and sudden unexpected death. Circulation 1987, 75:II4.
10. Ergin A., Muntner P., Sherwin R., et al. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004, 117:219.
11. Arciero T.J., Jacobsen S.J., Reeder G.S., et al. Temporal trends in the incidence of coronary disease. Am J Med 2004, 117:228.
12. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001, 104:2855.
13. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747.
14. Goyal A., Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006, 124:235.
15. Critchley J., Liu J., Zhao D., et al. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004, 110:1236.
16. Rodríguez T., Malvezzi M., Chatenoud L., et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970-2000. Heart 2006, 92:453.
17. Furman M.I., Dauerman H.L., Goldberg R.J., et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. JAm Coll Cardiol 2001, 37:1571.
18. Rogers W.J., Frederick P.D., Stoehr E., et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008, 156:1026.
19. Chen J., Normand S.L., Wang Y., et al. Recent declines in hospitalizations for acute myocardial infarction for Medicare fee-for-service beneficiaries: progress and continuing challenges. Circulation 2010, 121:1322.
20. Hardoon S.L., Whincup P.H., Lennon L.T., et al. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008, 117:598.
21. Roger V.L., Weston S.A., Gerber Y., et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation 2010, 121:863.
22. Parikh N.I., Gona P., Larson M.G., et al. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study. Circulation 2009, 119:1203.
23. Kuulasmaa K., Tunstall-Pedoe H., Dobson A., et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000, 355:675.
24. McGovern P.G., Pankow J.S., Shahar E., et al. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. NEngl J Med 1996, 334:884.
25. Capewell S., Morrison C.E., McMurray J.J. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999, 81:380.
26. Capewell S., Beaglehole R., Seddon M., et al. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000, 102:1511.
27. Cooper R., Cutler J., Desvigne-Nickens P., et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000, 102:3137.
28. McGovern P.G., Jacobs D.R., Shahar E., et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001, 104:19.
29. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. NEngl J Med 1998, 339:861.
30. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. NEngl J Med 2007, 356:2388.
31. Tu J.V., Nardi L., Fang J., et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke 1994-2004. CMAJ 2009, 180:1304.
32. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728.
33. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544.
34. Sheifer S.E., Manolio T.A., Gersh B.J. Unrecognized myocardial infarction. Ann Intern Med 2001, 135:801.
35. Kannel W.B., Cupples L.A., Gagnon D.R. Incidence, precursors and prognosis of unrecognized myocardial infarction. Adv Cardiol 1990, 37:202.
36. de Torbal A., Boersma E., Kors J.A., et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006, 27:729.
37. Jónsdóttir L.S., Sigfusson N., Sigvaldason H., et al. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J 1998, 19:1011.
38. Sigurdsson E., Thorgeirsson G., Sigvaldason H., et al. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995, 122:96.
39. Kannel W.B. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985, 110:1100.
40. Davidoff R., Goldman A.P., Diamond T.H., et al. The natural history of the Q wave in inferoposterior myocardial infarction. SAfr Med J 1982, 61:611.
41. Richter A., Herlitz J., Hjalmarson A. QRS complex recovery during one year after acute myocardial infarction. Clin Cardiol 1987, 10:16.
42. Kannel W.B., Dannenberg A.L., Abbott R.D. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 1985, 109:581.
43. Shlipak M.G., Elmouchi D.A., Herrington D.M., et al. The incidence of unrecognized myocardial infarction in women with coronary heart disease. Ann Intern Med 2001, 134:1043.
44. Deedwania P.C. Should asymptomatic subjects with silent ischemia undergo further evaluation and follow-up?. Int J Cardiol 1994, 44:101.
45. Deedwania P.C. The need for a cost-effective strategy to detect ambulatory silent ischemia. Am J Cardiol 1994, 74:1061.
46. Kannel W.B., Doyle J.T., McNamara P.M., et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975, 51:606.
47. Kannel W.B., Wilson P.W., D'Agostino R.B., et al. Sudden coronary death in women. Am Heart J 1998, 136:205.
48. Gillum R.F. Sudden coronary death in the United States: 1980-1985. Circulation 1989, 79:756.
49. Kannel W.B., Cupples L.A., D'Agostino R.B. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987, 113:799.
50. Berger C.J., Murabito J.M., Evans J.C., et al. Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992, 268:1545.
51. Chugh S.S., Uy-Evanado A., Teodorescu C., et al. Women have a lower prevalence of structural heart disease as a precursor to sudden cardiac arrest: The Ore-SUDS (Oregon Sudden Unexpected Death Study). JAm Coll Cardiol 2009, 54:2006.
52. Kim C., Fahrenbruch C.E., Cobb L.A., et al. Out-of-hospital cardiac arrest in men and women. Circulation 2001, 104:2699.
53. Kannel W.B., McGee D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8.
54. Kannel W.B., McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2:120.
55. Almdal T., Scharling H., Jensen J.S., et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004, 164:1422.
56. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595.
57. Zavaroni I., Bonora E., Pagliara M., et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. NEngl J Med 1989, 320:702.
58. Al-Delaimy W.K., Merchant A.T., Rimm E.B., et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004, 116:236.
59. Gerstein H.C., Pais P., Pogue J., et al. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. JAm Coll Cardiol 1999, 33:612.
60. Singer D.E., Nathan D.M., Anderson K.M., et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992, 41:202.
61. Vaccaro O., Eberly L.E., Neaton J.D., et al. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004, 164:1438.
62. Gansevoort R.T., Correa-Rotter R., Hemmelgarn B.R., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013, 382:339.
63. Stamler J., Stamler R., Neaton J.D., et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999, 282:2012.
64. Vasan R.S., Sullivan L.M., Wilson P.W., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005, 142:393.
65. Wilson P.W. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994, 7:7S.
66. Lloyd-Jones D.M., Hong Y., Labarthe D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010, 121:586.
67. Rimm E.B., Ascherio A., Giovannucci E., et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996, 275:447.
68. Wolk A., Manson J.E., Stampfer M.J., et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 1999, 281:1998.
69. Law M.R., Morris J.K. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease?. Eur J Clin Nutr 1998, 52:549.
70. Vanharanta M., Voutilainen S., Lakka T.A., et al. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999, 354:2112.
71. Vanharanta M., Voutilainen S., Rissanen T.H., et al. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2003, 163:1099.
72. Dauchet L., Amouyel P., Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. Neurology 2005, 65:1193.
73. Dehghan M., Mente A., Teo K.K., et al. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation 2012, 126:2705.
74. Bernstein A.M., Sun Q., Hu F.B., et al. Major dietary protein sources and risk of coronary heart disease in women. Circulation 2010, 122:876.
75. Pan A., Sun Q., Bernstein A.M., et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012, 172:555.
76. Powell K.E., Thompson P.D., Caspersen C.J., et al. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 1987, 8:253.
77. Paffenbarger R.S., Hyde R.T., Wing A.L., et al. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. NEngl J Med 1993, 328:538.
78. Leon A.S., Connett J., Jacobs D.R., et al. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. JAMA 1987, 258:2388.
79. Lee D.C., Sui X., Artero E.G., et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation 2011, 124:2483.
80. Sandvik L., Erikssen J., Thaulow E., et al. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. NEngl J Med 1993, 328:533.
81. Blair S.N., Kohl H.W., Paffenbarger R.S., et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989, 262:2395.
82. LaMonte M.J., Eisenman P.A., Adams T.D., et al. Cardiorespiratory fitness and coronary heart disease risk factors: the LDS Hospital Fitness Institute cohort. Circulation 2000, 102:1623.
83. Laukkanen J.A., Lakka T.A., Rauramaa R., et al. Cardiovascular fitness as a predictor of mortality in men. Arch Intern Med 2001, 161:825.
84. Myers J., Prakash M., Froelicher V., et al. Exercise capacity and mortality among men referred for exercise testing. NEngl J Med 2002, 346:793.
85. Barlow C.E., Defina L.F., Radford N.B., et al. Cardiorespiratory fitness and long-term survival in "low-risk" adults. JAm Heart Assoc 2012, 1:e001354.
86. Eckel R.H., York D.A., Rössner S., et al. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004, 110:2968.
87. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of U.S. adults. NEngl J Med 1999, 341:1097.
88. Wolk R., Berger P., Lennon R.J., et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292.
89. Tirosh A., Shai I., Afek A., et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. NEngl J Med 2011, 364:1315.
90. Januzzi J.L., Stern T.A., Pasternak R.C., et al. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med 2000, 160:1913.
91. Siegman A.W., Kubzansky L.D., Kawachi I., et al. Aprospective study of dominance and coronary heart disease in the Normative Aging Study. Am J Cardiol 2000, 86:145.
92. Kawachi I., Sparrow D., Spiro A., et al. Aprospective study of anger and coronary heart disease. The Normative Aging Study. Circulation 1996, 94:2090.
93. Sesso H.D., Kawachi I., Vokonas P.S., et al. Depression and the risk of coronary heart disease in the Normative Aging Study. Am J Cardiol 1998, 82:851.
94. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007.
95. Koenig W., Sund M., Fröhlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237.
96. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731.
97. Ridker P.M., Buring J.E., Rifai N., et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297:611.
98. Wilson P.W., Pencina M., Jacques P., et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92.
99. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499.
100. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009, 25:567.
101. U.S.Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151:474.
102. Sarwar N., Butterworth A.S., Freitag D.F., et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379:1205. IL6R Genetics Consortium Emerging Risk Factors Collaboration.
103. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012, 379:1214. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.
104. Reich D., Patterson N., Ramesh V., et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007, 80:716.
105. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. NEngl J Med 2003, 349:1595.
106. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. JClin Invest 2004, 114:529.
107. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136.
108. Karakas M., Koenig W., Zierer A., et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. JIntern Med 2012, 271:43.
109. Tang W.H., Tong W., Troughton R.W., et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. JAm Coll Cardiol 2007, 49:2364.
110. Grover S.A., Coupal L., Gilmore N., et al. Impact ofdyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005, 95:586.
111. Kamin D.S., Grinspoon S.K. Cardiovascular disease in HIV-positive patients. AIDS 2005, 19:641.
112. Currier J.S., Lundgren J.D., Carr A., et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29.
113. Grinspoon S.K., Grunfeld C., Kotler D.P., et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008, 118:198.
114. Tseng Z.H., Secemsky E.A., Dowdy D., et al. Sudden cardiac death in patients with human immunodeficiency virus infection. JAm Coll Cardiol 2012, 59:1891.
115. Moslehi J. The cardiovascular perils of cancer survivorship. NEngl J Med 2013, 368:1055.
116. Darby S.C., Ewertz M., McGale P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. NEngl J Med 2013, 368:987.
117. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769.
118. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. JAm Coll Cardiol 2007, 49:403.
119. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812.
120. Toth P.P., Massaro J., Jones S., et al. Quantitative impact of remnant lipopriteins on risk for hard CHD events: a meta-analysis of the Framinham Offspring and Jackson Heart Studies. JAm Coll Cardiol 2014, 63(12_S). 10.1016/S0735-1097(14)61317-6.
121. Mann J.F., Gerstein H.C., Yi Q.L., et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. JAm Soc Nephrol 2003, 14:641.
122. Roberts R., Steward A.F. Genes and coronary artery disease: where are we?. JAm Coll Cardiol 2012, 18:1715-1721.